Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Breast Neoplasms 1888Carcinoma, Non-Small-Cell Lung 1348Prostatic Neoplasms 980Colorectal Neoplasms 851Multiple Myeloma 741Leukemia, Myeloid, Acute 725Neoplasms 691Lung Neoplasms 679Neoplasm Metastasis 642Lymphoma 579Carcinoma, Hepatocellular 571Pancreatic Neoplasms 566Stomach Neoplasms 522Leukemia 511Recurrence 493Leukemia, Lymphocytic, Chronic, B-Cell 459Precursor Cell Lymphoblastic Leukemia-Lymphoma 452Melanoma 451Lymphoma, Non-Hodgkin 442Ovarian Neoplasms 426Lymphoma, Large B-Cell, Diffuse 423Squamous Cell Carcinoma of Head and Neck 416Myelodysplastic Syndromes 416Head and Neck Neoplasms 403Brain Neoplasms 403Rectal Neoplasms 397Glioblastoma 375Carcinoma, Renal Cell 350Hodgkin Disease 338Esophageal Neoplasms 337

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × OTHER × EBV Lymphomas × Clear all
NCT03988582 2020-06-11

Safety and Effectiveness of EBV-specific Cytotoxic T Cells for the Treatment for EBV Lymphomas or Other EBV-associated Malignancies

Memorial Sloan Kettering Cancer Center

Phase 2 Withdrawn
Lymphoid

EBV Lymphomas

Data powered by HemOnc (CC BY 4.0) Colophon âš¡